Mesenchymal stromal cell function is not affected by drugs used in the treatment of inflammatory bowel disease

Duijvestein, M.; Molendijk, I.; Roelofs, H.; Vos, A.C.W.; Verhaar, A.P.; Reinders, M.E.J.; ... ; Hommes, D.W. (2011)

Article / Letter to editor

Background and aims. Mesenchymal stromal cells (MSC) have both multilineage differentiation capacity and immunosuppressive properties. Promising results with MSC administration have been obtained in experimental colitis. Clinical application of MSC for the treatment of inflammatory bowel disease (IBD) is currently under investigation in phase I-III trials in patients with past or concurrent immunomodulating therapy. However, little is known about MSC interactions with these immunosuppressive drugs. To address this issue we studied the combined effect of MSC and IBD drugs in in vitro functionality assays. Methods. The effects of azathioprine, methotrexate, 6-mercaptopurine and anti-tumor necrosis factor (TNF)-alpha on MSC phenotype, survival, differentiation capacity and immunosuppressive capacity were studied. Results. MSC exposed to physiologically relevant concentrations of IBD drugs displayed a normal morphology and fulfilled phenotypic and functional criteria for MSC. Differentiation into adipocyte and osteocyte lineages was not affected and cells exhibited normal survival after exposure to the various drugs. MSC suppression of peripheral blood mononuclear cell (PBMC) proliferation in vitro was not hampered by IBD drugs. In fact, in the presence of 6-mercaptopurine and anti-TNF-alpha antibodies, the inhibitory effect of this drug alone was enhanced, suggesting an additive effect of pharmacotherapy and MSC treatment. Conclusions. This study demonstrates that, in vitro, MSC phenotype and function are not affected by therapeutic concentrations of drugs commonly used in the treatment of IBD. These findings are important for the potential clinical use of MSC in combination with immunomodulating drugs and anti-TNF-alpha therapy.

• anti-tumor necrosis factor-alpha Crohn's disease immunomodulators medication mesenchymal stromal cell low-dose methotrexate antitumor necrosis factor stem-cells in-vitro crohns-disease mononuclear-cells peripheral-blood interferon-gamma progenitor cells clinical-trial

• All authors: Duijvestein, M.; Molendijk, I.; Roelofs, H.; Vos, A.C.W.; Verhaar, A.P.; Reinders, M.E.J.; Fibbe, W.E.; Verspaget, H.W.; Brink, G.R. van den; Wildenberg, M.E.; Hommes, D.W.
• Date: 2011-10-31
• Journal: Cytotherapy
• Volume: 13
• Issue: 9
• Pages: 1066 - 1073
• DOI: doi:10.3109/14653249.2011.597379